After months of hard work, we are proud to unveil the new Enlivex website, the home for everything we are building. I have spent decades navigating the capital-intensive cycles of the life sciences. If my tenure leading PROLOR through a $590 million exit and partnering with

I am often asked why I chose biotech. I do not have a PhD, and I am not a scientist. My background is pure finance. But after decades on Wall Street, I moved back home and found myself at a crossroads: "What's next?" I did not want to go back into the same old rooms. And so I

Online search interest in longevity has reached its highest point on record in the United States. As access to modern healthcare expands and life expectancy increases, people are naturally beginning to think further into the future. But the mainstream longevity conversation

Today, the FDA cleared our IND application to initiate a Phase 2b trial of Allocetra in patients with age-related primary knee osteoarthritis. Global life expectancy has more than doubled since 1900. But the science of living longer has outpaced the science of living better. For

I have spent my career building companies where the science and the capital structure had to work together. At PROLOR, we learned that a breakthrough therapy means nothing without the financial architecture to see it through. That lesson is built into everything we are doing at

This morning, Enlivex reported $1.23 Billion in total net profit for 2025 and $25.48 Earnings Per Share. A year ago we were posting a net loss. Today's results are a reflection of the architecture we built and the team that executed it. I believe we are only at the beginning of

The numbers we are reporting today are the result of a model we built from the ground up. I believe the intersection of quality longevity science and prediction markets infrastructure represents one of the most compelling investment opportunities in public markets today.

1.23 billion dollars in net profit. $25.48 EPS. 2.31 billion in treasury and treasury-related assets. 5.5 million in total liabilities. A clinical program advancing toward Phase 2b. A treasury anchored in the economics of prediction markets. Two strategies, each generating value

Quite a week.... From the $1.23 billion in net profit to the Allocetra FDA clearance for Phase 2b, last week was an important milestone in the validation of the Enlivex architecture. Another step forward with therapy that potentially sets the stage for quality longevity years.

How can a clinical-stage company decouple its capital structure from the dilution cycle that typically defines the category? At Enlivex, the answer was to anchor the corporate treasury in the prediction markets economy. A programmatic mechanism tied to forecasting activity

Enlivex is now part of the $1 billion tokenized stock market. Ondo Finance has just launched ENLVon, a tokenized representation of ENLV ordinary shares on its Global Markets platform. This extends the investment reach of our dual-strategy model from traditional capital markets